Biologics

Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, totaled $186 million in fourth quarter sales, according to Stat.

Here are eight things to know about the spinal fusion market.

In February, Ryan Woods, MD, will provide regenerative medicine services to patients at Orthopedics & Sports Medicine BayCare Clinic in Manitowoc, Wis., according to the Herald Times Reporter.

NanoFUSE Biologics appointed Answorth Allen, MD, Jan. 16 to its scientific advisory board, reports Benzinga.

The potential of spine-targeted biologics is immense and quickly developing. Here are four recent stories on notable developments or recognitions:

Stem Cells Translational Medicine recently awarded Mohamad Khazaei, PhD, its Young Investigator Award for his research on cell-based treatments for spinal cord injuries, reports News Medical Life Sciences.

Orthobiologic developer Bone Biologics said its rhNELL-1 product promoted bone formation in advanced spine models.

Developmental biologist Olivier Pourquié, PhD, identified a cellular segmentation clock-like mechanism in humans that controls spine development, The Harvard Gazette reports.

Ortho-biologics company Royal Biologics launched Magnus, a DMSO-free viable cellular bone allograft, the first of its kind to be DMSO-free.

NanoFUSE Biologics named Darren Lebl, MD, to its scientific advisory board.